cd103-overexpressing regulatory t cells

CD103-overexpressing regulatory T cells are engineered or selectively expanded FoxP3+ regulatory T lymphocytes that express high levels of the αE integrin CD103 (integrin αEβ7), which binds E‑cadherin and promotes tissue retention and localization within epithelial and tumor microenvironments. CD103+ Tregs have been identified as a highly suppressive subset in multiple settings, including tumors and inflamed tissues, characterized by potent inhibition of effector T-cell activation and elevated production of immunoregulatory mediators such as IL‑10, often driven by local TGF‑β signaling.[1][4][7][9] As an investigative cell therapy concept, CD103-overexpressing Tregs are being explored preclinically as a way to enhance local immune regulation in diseases where excessive type 1 or type 2 inflammation and tissue damage need to be controlled, while in oncology the same subset is typically viewed as a resistance mechanism to immunotherapy rather than a direct therapeutic product.

Other names

CD103-overexpressing Treg cellsCD-103-overexpressing Treg cellsCD 103-overexpressing Treg cellsCD103+ regulatory T cellsCD103+ Treg cells